Skip to Content
Event

Capgemini at BioTechX 2025

October 6-8, 2025
Hall 1.2, Messe Basel, Switzerland
Booth: #513

Innovation, meet health.

The synergy between innovation and healthcare is not just about advancing technology; it’s about breaking down the barriers that sometimes hinder seamless care delivery and progress in life sciences. At Capgemini, we’re all about transforming data and research into real results, pushing pharma into the future while caring for humanity. That’s why we’re thrilled to be part of BioTechX Europe 2025, showcasing our innovation power and our AI and data integration capabilities and expertise.

What’s BioTechX Europe?

BioTechX Europe is the go-to event for diagnostics, precision medicine, and digital transformation in pharma and healthcare. This year, again in Basel, Europe’s pharma hub, with 3000 global execs, 400 speakers, and 50 start-ups all under one roof.

The event is packed with networking opportunities and insights from top pharmaceutical and biotech companies, healthcare systems providers, and academic groups.

The full agenda can be found here

Join Our expert-led panel discussions at BioTechX

At BioTechX, we will be moderating panel discussions and present on critical topics such as data integration, Agentic AI, and GenAI in preclinical science. These discussions will feature industry leaders and experts, providing valuable insights and fostering collaboration in the biotech community. Join us as we explore these pivotal areas and contribute to the advancement of biotechnology.

Making a splash

Long story short, we’re not just attending—we want to make a splash. In our booth we will be showcasing different demos and we will be on stage and moderating panel discussion, showing we mean business.

Join us at BioTechX Europe 2025 in Basel and be part of the future of biotech and pharma.

Key takeaways from 2024

Where to find us

From molecule to mandate: How Gen AI is redefining preclinical science and regulatory strategy​

Moderated by Ivana Knyght, Ph.D​, Capgemini​ Invent, this panel will explore how generative AI is transforming the regulatory and scientific landscape – from enabling in silico alternatives to animal testing, to revolutionizing how regulatory dossiers are authored, reviewed, and approved. With the FDA accelerating its initiatives around AI, the industry is at a pivotal moment to rethink how we bring therapies to market faster and more efficiently.

Pharmaceutical superintelligence: Transforming drug discovery with AI​

Join us for an inside look at how Capgemini and Insilico Medicine are partnering to develop Pharmaceutical Superintelligence (PSI) — a groundbreaking AI system designed to revolutionize the pharmaceutical industry. This session will explore how PSI leverages generative AI, predictive modeling, and automation to accelerate drug discovery and development. Learn how this collaboration is reshaping the future of medicine by enabling faster, safer, and more personalized treatments through data-driven innovation.​

Presenters:

  • Dr. Parvin Moyassari​, Capgemini​, Global Head of Life Sciences-Insight & Data
  • Dr. Petrina Kamya​, Insilico Medicine Canada​, VP, Global Head of AI Platforms, President

Predicting outcomes, accelerating therapies through integrated data: The role of federated big data systems to inform next-gen analytics like digital twins

Moderated by Justin Melnick, Capgemini Invent, this panel will explore how a collaborative, cross-sector approach, uniting industry leaders and academic institutions, can unlock the full potential of integrated data and federated learning to transform R&D in complex disease areas. Focusing on osteoarthritis (OA) as a case study, the discussion will highlight how these technologies can overcome long-standing barriers in clinical research, particularly in diseases with high prevalence and socio-economic burden. By embedding disease progression modeling within next-generation analytics such as digital twins, this approach offers a path toward more predictive, efficient, and outcome-driven therapeutic development – bringing new hope to millions of patients worldwide.

Panelists:

  • Matthias Schieker, Prof. Dr. med.​, Novartis​, Vice President, Sr. Distinguished Fellow – Translational Medicine
  • Laura Witkam, Global Project Head Early Development I&I, Sanofi
  • Jan Baumbach, Ph.D, Professor at University of Hamburg, Director of the Institute for Computational Systems Biology, “CSO” of the Dehaze GmbH and the Omiy.ai GmbH (i.Gr.)

If you’d like to meet us at BioTechX or have any questions, please fill out the form, and we’ll get back to you promptly.

Slide to submit

We are sorry, the form submission failed. Please try again.

Meet our experts

Justin Melnick

Justin Melnick

R&D Transformation Partner Life Sciences
Justin leads Capgemini’s R&D for life sciences offer and is focused on the translatory role between the worlds of computational and biological sciences. He has 12 years experience in figuring out how to utilize technology to fundamentally impact human lives. A firm believer in tech-for-good and energized by the opportunity and ability to utilize technology in new ways that rewrite the business models of the life sciences world.
Dr. Parvin Moyassari

Dr. Parvin Moyassari

Global Head of Life Sciences, Insight & Data – Capgemini
Parvin leads Capgemini’s global Life Sciences at Insight & Data practice, where she brings together scientific depth and digital innovation to transform life sciences industry. With over 18 years of experience in AI, data analytics and digital transformation, she drives strategic initiatives that unlock the power of data and AI to improve health outcomes, streamline operations, and enable smarter decision-making. Her work is at the forefront of shaping the future of pharmaceutical intelligence, bridging cutting-edge technology with real-world impact.
Ivana Knyght

Ivana Knyght

VP & Global Life Sciences Accelerator Lead, Capgemini Invent
Ivana is an established Life Sciences leader bringing a wealth of scientific, research, clinical and data expertise gained over the past 15+ years. At Capgemini, Ivana is at the forefront of driving digital innovation, business transformation and R&D acceleration for her clients. She provides strategic and scientific expertise to develop innovative solutions by employing emerging technologies, assets and platforms. She leads CxO-level business development, strategic deal shaping, and partnership building.